Wave Life Sciences Ltd.WVEEarnings & Financial Report
BIT Life Sciences is a for profit meetings, incentives, conferencing, exhibitions (MICE) company based in Dalian, China, that specializes in arranging multiple scientific congresses that have been described as "predatory". The company is part of a wave of organizations that have appeared in China in the past several years noted for arranging congresses with little academic merit and with the primary aim of generating revenue rather than scientific knowledge sharing. Papers submitted are usual...
Revenue
$49.2M
Gross Profit
N/A
Operating Profit
$4.4M
Net Profit
$7.3M
Gross Margin
N/A
Operating Margin
9.0%
Net Margin
14.7%
YoY Growth
17168.1%
EPS
$0.07
Wave Life Sciences Ltd. Q3 FY2023 Financial Summary
Wave Life Sciences Ltd. reported revenue of $49.2M (up 17168.1% YoY) for Q3 FY2023, with a net profit of $7.3M (up 118.6% YoY) (14.7% margin).
Key Financial Metrics
| Total Revenue | $49.2M |
|---|---|
| Net Profit | $7.3M |
| Gross Margin | N/A |
| Operating Margin | 9.0% |
| Report Period | Q3 FY2023 |
Wave Life Sciences Ltd. Annual Revenue by Year
Wave Life Sciences Ltd. annual revenue history includes year-by-year totals (for example, 2023 revenue was $113.3M).
| Year | Annual Revenue |
|---|---|
| 2023 | $113.3M |
Wave Life Sciences Ltd. Quarterly Revenue & Net Profit History
Wave Life Sciences Ltd. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q2 FY2025 | $8.7M | -55.8% | $-50.5M | -580.2% |
| Q1 FY2025 | $9.2M | -26.8% | $-46.9M | -510.9% |
| Q2 FY2024 | $19.7M | -10.9% | $-32.9M | -167.2% |
| Q1 FY2024 | $12.5M | -3.0% | $-31.6M | -251.7% |
| Q4 FY2023 | $29.1M | +2245.1% | $-16.3M | -55.9% |
| Q3 FY2023 | $49.2M | +17168.1% | $7.3M | 14.7% |
| Q2 FY2023 | $22.1M | +5794.9% | $-21.1M | -95.5% |
| Q1 FY2023 | $12.9M | +638.8% | $-27.4M | -212.0% |
Income Statement
| Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q1 2025 | Q2 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $12.9M | $22.1M | $49.2M | $29.1M | $12.5M | $19.7M | $9.2M | $8.7M |
| YoY Growth | 638.8% | 5794.9% | 17168.1% | 2245.1% | -3.0% | -10.9% | -26.8% | -55.8% |
Balance Sheet
| Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q1 2025 | Q2 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $267.3M | $230.0M | $199.9M | $274.9M | $235.3M | $208.8M | $288.3M | $252.4M |
| Liabilities | $294.1M | $273.8M | $232.5M | $227.4M | $202.0M | $204.4M | $108.7M | $105.2M |
| Equity | $-34.7M | $-51.7M | $-40.5M | $39.6M | $25.4M | $-3.5M | $171.8M | $139.3M |
Cash Flow
| Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q1 2025 | Q2 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $85.5M | $-37.3M | $-34.5M | $-33.2M | $-33.4M | $-27.5M | $-63.0M | $-46.0M |